However, long-term studies specifically tracking extended use are lacking
Heffernan, R
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Now that we have forged links with the BSH we look forward to being involved in all manner of activities in the future
In preclinical data, the pair improves adipocyte NAD+ by inhibiting NNMT, resulting in better fat metabolism and reduced obesity.[8][3] For anti-aging, this translates to improved tissue resilience and reduced senescence
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research